Novel therapies that antagonize the systemic FGF23 excess in XLH children significantly improve rickets and osteomalacia, but do not have a dramatic effect on growth velocity in clinical trials and reports [25–29, 35]. This evidence concerns the gene FGF23 and osteomalacia.